[] A notable distinction between oral melanotic macule and primary oral melanoma was observed in terms of age, gender, and lesion location
GLP-1/glucagon co-agonists The development of these unimolecular formulations targeting both GLP-1 and glucagon receptors enhances the anorectic effect of GLP-1, provides a lipolytic and lipogenesis-inhibiting effect (Table 2)particularly at the hepatic leveland promotes thermogenic activity, thereby facilitating weight reduction and the treatment of MASLD.1,5,35 Survodutide generates dose-dependent weight reduction of up to 14.9% in 46 weeks.49 It is shown to be effective in reducing liver fat and improving MASH in up to 62% of participants treated with weekly injection of 4.8 mg
Peer-reviewed research on tesamorelin consistently confirms its mechanism as a growth hormone secretagogue with targeted effects on visceral adiposity, making it distinct from general fat loss agents
GLP-1 Agonists Can Disrupt Gut Health These medications slow down digestion, increasing food exposure to gut bacteria
You can lose weight, but it also may affect your digestion